Olivier Chesnoy

Chief Executive Officer at TECHNOFLEX

65 year

Process Industries

Health Technology

Profile

Olivier Chesnoy is currently the Chairman-Management Board at Technoflex SAS since 2011.
Prior to this, he was the Chairman & Chief Executive Officer at Theraptosis SA from 2009 to 2010.

Olivier Chesnoy active positions

Companies	Position	Start
TECHNOFLEX	Chief Executive Officer	08/09/2011

All active positions of Olivier Chesnoy

Former positions of Olivier Chesnoy

Companies	Position	End
Theraptosis SA Theraptosis SA Pharmaceuticals: MajorHealth Technology Theraptosis S.A. , a biotechnology company, was founded in April 2001. Theraptosis designs and develops various drugs that act on key apoptosis regulators to fight diseases associated with lack or excess of apoptosis including cancer and neurodegenerative diseases. The Company's key assets include a dual technology platform (CytoTrust™ and MitoTrust™) for screening and targeting purposes and a pipeline of products in the areas of CNS and oncology. Theraptosis' discovery engines integrate mitochondria, and apoptosis expertise, and has developed pre-clinical animal models.	Chairman	10/03/2010

See the detail of Olivier Chesnoy's experience

Experiences
Positions held

Active

Inactive

Listed companies

Private companies

See the detail of Olivier Chesnoy's experience

Connections

1st degree connections

1st degree companies

Male

Female

Members of the board

Executives

See the personal network

Linked companies

Private companies	2
Technoflex SAS Technoflex SAS Chemicals: Major DiversifiedProcess Industries Technoflex SAS engages in the design, manufacture, and marketing of flexible containers for pharmaceutical industry. Its therapeutic applications include IV therapies, cell therapy, and biopharmaceuticals. The company's products include sterile bags, multi-chamber bags, and connectors. It also provides turnkey solutions and generic drug dossiers. The company was founded by Jacques Ponlot in 1972 and is headquartered in Bidart, France.	Process Industries
Theraptosis SA Theraptosis SA Pharmaceuticals: MajorHealth Technology Theraptosis S.A. , a biotechnology company, was founded in April 2001. Theraptosis designs and develops various drugs that act on key apoptosis regulators to fight diseases associated with lack or excess of apoptosis including cancer and neurodegenerative diseases. The Company's key assets include a dual technology platform (CytoTrust™ and MitoTrust™) for screening and targeting purposes and a pipeline of products in the areas of CNS and oncology. Theraptosis' discovery engines integrate mitochondria, and apoptosis expertise, and has developed pre-clinical animal models.	Health Technology